The TriHealth Hatton Research Institute's Oncology research team, and researchers at TriHealth’s Cancer Institute and Mary Jo Cropper Family Center for Breast Care conduct important clinical trials targeting improvements in the prevention and treatment of specific kinds of cancer. Composed of a team of research nurses and clinical research assistants, the TriHealth Hatton Research Institute's Oncology research team has many decades of experience in oncology research.
Clinical trials supported by our Oncology research team include cooperative group trials sponsored by the National Cancer Institute, studies through the Catholic Health Initiative, and Pharmaceutical Trials.
Selected trials:
- Molecular Profiling
- Breast
- Gastrointestinal
- Genitourinary
- Gynecology
- Hematology
- Lung Cancer
- Melanoma/Skin
- Sarcoma
What is a Clinical Trial?
A clinical trial (also called “clinical research,” “research study,” and “protocol”) is a research study that evaluates a new test, drug or treatment in people to make sure it is safe and effective. Carefully conducted clinical trials are vital to discovering new, better, safer treatments for people, and improve health and quality of life.
Clinical trials are important today for many reasons, including:
- Contributing to improved scientific knowledge about cancer: how to detect it, and how to treat it, and even how to prevent it
- Possibly benefiting individual patients by providing newer and better treatments, and possibly, a cure
More Information
For additional basic information about clinical trials:
- Introduction to Cancer Research
- National Cancer Institute’s brochure: “Taking Part in Cancer Treatment Research Studies”
- National Cancer Institute website
- National Institutes of Health website
- National Comprehensive Cancer Network website
- National Cancer Institute video about volunteering for a clinical trial
- The American Cancer Society
Oncology: Molecular Profiling |
|
EAY131: Molecular Analysis for Therapy Choice (MATCH). Principal Investigator and Contact information: Study Coordinator and Contact information: Diann Fischesser, RN
Angela Hein, RN
Audrey Maschino, RN
|
|
S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors. Principal Investigator and Contact information: Study Coordinator and Contact information: |
Oncology: Breast |
|
A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant Treatment (ALTERNATE) in postmenopausal women: A Phase III Study. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (CT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWEL Study). Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
CADENCE: Carboplatin and Docetaxel in Neoadjuvant Treatment of ER Negative, HER2 Negative Breast Cancer. Learn more. Investigator and Contact information: Study Coordinator and Contact information: |
|
EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemo-therapy vs. Observation in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
FLEX: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
MK3475-522: A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed By Weekly Paclitaxel With Or Without Carboplatin For Node-Positive Or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG CC004: Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NSABP B51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy. Learn more . Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NSAPB B55: A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
S1207: Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3). Learn more. Principal Investigator and Contact information; Study Coordinator and Contact information: |
|
S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy. Learn more. Principal Investigator and Contact information:
Study Coordinator and Contact information:
|
|
WF 97116: A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment. Learn more. Principal Investigator and Contact information:
Study Coordinator and Contact information:
|
Oncology: Gastrointestinal |
|
A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
Oncology: Genitourinary |
|
EA8143: A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC). Learn more. Principal Investigator and Contact information:
Study Coordinator and Contact information:
|
Oncology: Gynecology |
|
GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG GY005: A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS). Learn more . Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer. Learn more. Principal Investigator and Contact information:
Study Coordinator and Contact information:
|
|
NRG CC004: Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer Learn more . Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
LCCC 1326: Metformin with the Levonorgestrel-Releasing Intrauterine Device for the treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
Oncology: Hematology |
|
C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6). Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
PIPER: A Prospective, Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
S1702: A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
MT3724_NHL_002: A Phase 2a Open-label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory CD20-positive B-Cell Non-Hodgkin Lymphoma. Learn More. Principal Investigator: Study Coordinator and Contact Information: |
Oncology: Lung Cancer |
|
A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105 and E4512. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo In Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC). An ALCHEMIST Treatment Trial. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
E4512: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations. An ALCHEMIST Treatment Trial. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
Oncology: Melanoma/Skin |
|
CO39722: A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
20130193: A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers; and Long-term Safety in Treated Patients. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
Oncology: Sarcoma |
|
A091401: Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |